Comparative Efficacy and Safety of Oral P2Y 12 Inhibitors in Acute Coronary Syndrome

Structured PICO

Do prasugrel and ticagrelor reduce ischemic events and mortality compared to clopidogrel in patients with acute coronary syndrome?

Population

Patients with Acute Coronary Syndrome

Intervention

Prasugrel and ticagrelor (oral P2Y12 inhibitors)

Comparator

Clopidogrel

Outcome

Ischemic events, bleeding, and mortalityhard clinical

In acute coronary syndrome, prasugrel and ticagrelor provide superior ischemic protection but higher bleeding risk than clopidogrel, with ticagrelor uniquely showing a mortality benefit.

Abstract

Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison with clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42019155648.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Navarese et al. (Fri,) studied this question.

synapsesocial.com/papers/69cc63422893a4923719c809 https://doi.org/https://doi.org/10.1161/circulationaha.120.046786

Bookmark

View Full Paper